Edesa Biotech, Inc. has entered into a multi-year contribution agreement with the Government of Canada for funding towards a Phase 3 clinical study of its experimental drug EB05 for COVID-19 patients, with CAD $23 million committed, of which CAD $5.75 million is non-repayable.